STK11 and non-small cell lung carcinoma: The most frequent co-alteration associated with KRAS in 330 advanced NSCLC patients were TP53 (41%), STK11 (28%), KEAP1/NFE2L2 (27%), RBM10 (16%), and PTPRD (15%).